Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer

This study is testing a new type of immunotherapy called CAR-T cell therapy — where a patient's own immune cells are engineered to attack cancer — in people with advanced colorectal cancer. The CAR-T cells are designed to target two proteins (CDH17 and GUCY2C) found on colorectal cancer cells. **You may be eligible if...** - You have advanced colorectal cancer that has not responded to standard treatments or where standard treatments are not suitable - Your tumor has been tested and shows the CDH17 or GUCY2C proteins (by IHC test within the last 2 years) - You have at least one measurable tumor outside the brain - You are reasonably functional (ECOG score 0–1) with an expected survival of at least 3 months - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have brain cancer spread - You have had another cancer in the past 5 years - You have serious heart, liver, kidney, or lung disease - You have an autoimmune or inflammatory condition - You are pregnant or breastfeeding - You have had an organ transplant - You have an active infection requiring IV antibiotics Talk to your doctor to see if this trial is right for you.